We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

I always find myself rooting not necessarily for the actor who gave the best performance — because, really, who can say which ...

Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...

Just take a look at the healthcare sector. By all accounts, healthcare stocks should be in the dumps. The sector sold off ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.

This was the stock's fifth consecutive day of gains.

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...